- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05847218
Phase 1 Clinical Trial of RHN-001 in Healthy Adult Volunteers
A Single-Dose Phase 1 Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics of RHN-001 in Healthy Adult Volunteers.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is planned to be conducted in Two Phases (Cohort A and Cohort B). The first phase will be carried out in two Cohorts i.e., a single oral dose of investigational drug 750 mg or placebo under fasting (Cohort A1) and a single oral dose of investigational drug 750 mg or placebo under fed conditions (Cohort A2).
The second phase of the study will also be carried out in two cohorts i.e., a single oral dose of 1500 mg or placebo under fasting (Cohort B1) and a single oral dose of 1500 mg or placebo under fed conditions (Cohort B2).
Blood samples will be obtained from the volunteers at different time-points i.e. 0.0 hour (before dosing), 15.0 minutes, 30.0 minutes, 1.0 hour, 2.0, 3.0, 4.0, 8.0, 12.0 and 24.0 hours post-dose in each cohort.
Urine samples (10 mL) for PK analysis will be collected after dosing for 24 hours whenever the subjects feel to urinate during their stay at the clinical trial site.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Sindh
-
Karachi, Sindh, Pakistan, 75270
- Center for Bioequivalence Studies and clinical research (CBSCR), ICCBS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject's written informed consent obtained prior to any study-related procedures.
- Subject is a male/female with an age between 18 and 55 years of age, inclusive.
- Subject has a body mass index between 18 and 32 kg/m2, inclusive.
- Subject is judged to be in good health on the basis of medical history, complete physical examination, 12-lead electrocardiogram (ECG) and standard laboratory tests including complete hematology, blood chemistry, Lipid profile, Thyroid profile and urinalysis.
- Subject understands the procedures and agrees to participate in the study program.
Exclusion Criteria:
- Subject is under the age of legal consent, or is mentally or legally incapacitated.
- Subject has a history of any illness that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering RHN-001 to the subject.
- Subject has a recent history (10 years) of major cardiovascular, hepatic or renal disease.
- Subject has liver function tests abnormalities with elevated AST or ALT greater than or equal to 2 times upper limit of normal and/or elevated bilirubin greater than or equal to 2 times upper limit of normal.
- Subject has renal function tests abnormalities with serum creatinine greater than 1.8 g/dL.
- Subject has any clinically significant abnormal hematological values in the opinion of the principal investigator.
- Subject has abnormal serum concentrations of TSH, T3 or T4.
- Subject has clinically significant abnormalities at physical examination, ECG or laboratory tests carried out at screening.
- Subject has a history of psychiatric disorders, significant allergic conditions or known hypersensitivity to medications.
- Subject is positive on testing for hepatitis B surface antigen, hepatitis C antibody or HIV 1 or 2 antibodies or tested positive for COVID-19 on rapid antigen testing.
- Subject has donated blood within the 2 months before study drug administration.
- Subject has a history of alcohol or drug abuse within the past year.
- Subject used any over-the-counter drug during the 2 weeks prior to study drug administration (except occasional acetaminophen or vitamins).
- Subject is positive on urine drug screening for drugs of abuse (cannabinoids, cocaine, opiates, amphetamines, barbiturates, benzodiazepines).
- Subject tests positive for alcohol on Breath alcohol or urine screening.
- Subject smokes more than 5 cigarettes per day.
- Subject consumes caffeine more than 500 mg per day.
- Subjects unlikely to comply with the study protocol or unable to understand the nature and scope of the study or the possible benefits or unwanted effects of the study treatments.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A1 (750mg RHN-001 or Placebo) in fasting state
Eligible 16 subjects will be randomized in Cohort A1 (n=16; 12 active: 4 Placebo) and fast for at least 10 hours on check-in day after dinner till 4 hours after they receive the investigational product (RHN-001 750mg caplet) or placebo at the study site on the morning of Day 2 of the study.
|
Subjects in A1 and A2 will receive 750mg RHN-001 or matching placebo tablets in Fasted state and Fed states respectively with 240 mL ambient temperature water.
|
Experimental: Cohort A2 (750mg RHN-001 or Placebo) in fed state
Eligible 16 subjects will be randomized in Cohort A2 (n=16; 12 active: 4 Placebo) and will receive the investigational product (RHN-001) or placebo on Day 2 (dosing day) within 30 minutes after a standard breakfast.
All subjects will undergo a 24-hour PK study during their stay at the clinical trial site.
|
Subjects in A1 and A2 will receive 750mg RHN-001 or matching placebo tablets in Fasted state and Fed states respectively with 240 mL ambient temperature water.
|
Experimental: Cohort B1 (1500mg RHN-001 or Placebo) in fasting state
Eligible 16 subjects will be randomized in Cohort B1 (n=16; 12 active: 4 Placebo) and fast for at least 10 hours on check-in day after dinner till 4 hours after they receive the investigational product (RHN-001 1500mg caplet) or placebo at the study site on the morning of Day 2 of the study.
|
Subjects in B1 and B2 will receive 1500mg RHN-001 (750mg tablet) or matching placebo tablets in Fasted state and Fed states respectively with 240 mL ambient temperature water.
|
Experimental: Cohort B2 (1500mg RHN-001 or Placebo) in fed state
Eligible 16 subjects will be randomized in Cohort B2 (n=16; 12 active: 4 Placebo) and will receive the investigational product (RHN-001) or placebo on Day 2 (dosing day) within 30 minutes after a standard breakfast.
All subjects will undergo a 24-hour PK study during their stay at the clinical trial site.
|
Subjects in B1 and B2 will receive 1500mg RHN-001 (750mg tablet) or matching placebo tablets in Fasted state and Fed states respectively with 240 mL ambient temperature water.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability profile of SAD of RHN-001
Time Frame: up to 24 hours post dose in each cohort
|
Number of subjects with adverse events (AEs) (i.e., seriousness, severity, relationship to the study medication, outcome, duration, and management), vital signs, 12-lead electrocardiogram (ECGs), clinical laboratory parameters, weight, and physical examination.
|
up to 24 hours post dose in each cohort
|
Safety Endpoints of MAD of RHN-001
Time Frame: up to 24 hours post dose in each cohort
|
Number of subjects with adverse events (AEs) (i.e., seriousness, severity, relationship to the study medication, outcome, duration, and management), vital signs, 12-lead electrocardiogram (ECGs), clinical laboratory parameters, weight, and physical examination.
|
up to 24 hours post dose in each cohort
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
maximum plasma concentration
Time Frame: up to 24 hours post dose
|
maximum concentration of RHN-001 in plasma after dose in each cohort
|
up to 24 hours post dose
|
Time to reach maximum plasma concentration
Time Frame: up to 24 hours post dose
|
Time required for RHN-001 to reach maximum plasma concentration
|
up to 24 hours post dose
|
AUC (Area under concentration vs time curve)
Time Frame: up to 24 hours post dose
|
Area under the time versus plasma RHN-001 concentration curve
|
up to 24 hours post dose
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Muhammad Raza Shah, PhD, Center for bio-equivalence studies and clinical research, ICCBS, University of Karachi, Pakistan
- Principal Investigator: Izhar Hasan, MD, PhD, RH Nanopharmaceuticals LLC, Princeton, NJ 088540
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CB-046-RHN(S)-2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pharmacokinetics
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Subjects | Pharmacokinetics of Isavuconazole | Pharmacokinetics of Methotrexate | Pharmacokinetics of 7-hydroxymethotrexateUnited States
-
Astellas Pharma IncCompletedHealthy | Pharmacokinetics of ASP1941 | Pharmacokinetics of MitiglinideJapan
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of MethadoneUnited States
-
Astellas Pharma IncBasilea PharmaceuticaCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of MidazolamUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of DigoxinUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of BupropionUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Subjects | Pharmacokinetics of Isavuconazole | Pharmacokinetics of SirolimusUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of AtorvastatinUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Subjects | Pharmacokinetics of Caffeine | Pharmacokinetics of RepaglinideUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Subjects | Pharmacokinetics of Isavuconazole | Pharmacokinetics of MetforminUnited States
Clinical Trials on RHN-001 (one tablet 750mg)
-
BiondVax Pharmaceuticals ltd.Completed
-
Sinew Pharma Inc.Completed
-
Fulcrum TherapeuticsCompletedHealthy Adult SubjectsUnited States
-
TaiGen Biotechnology Co., Ltd.Completed
-
OhioHealthCompletedKnee OsteoarthritisUnited States
-
Andrew CarrViiV Healthcare Australia Pty. LtdCompletedHuman Immunodeficiency VirusAustralia
-
University of Maryland, BaltimoreTerminatedDiabetes Mellitus, Type 2United States
-
Oslo University HospitalRecruitingCentral Retinal Artery OcclusionDenmark, Norway, Belgium, Sweden, Finland, Ireland, Lithuania, Australia, Austria